NASDAQ:CODX - Co-Diagnostics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Co-Diagnostics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.03 +0.90 (+79.65 %) (As of 01/24/2020 06:07 AM ET) Add Compare Today's Range$1.82Now: $2.03▼$2.8050-Day Range$0.90MA: $1.02▼$2.0352-Week Range$0.69Now: $2.03▼$3.77Volume35.96 million shsAverage Volume200,427 shsMarket Capitalization$34.75 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CODX Previous Symbol CUSIPN/A CIK1692415 Webhttp://www.codiagnostics.com/ Phone801-438-1036Debt Debt-to-Equity RatioN/A Current Ratio10.01 Quick Ratio9.96Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$40,000.00 Price / Sales868.84 Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-25.38Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-6,270,000.00 Net Margins-5,486.08% Return on Equity-202.74% Return on Assets-152.56%Miscellaneous Employees22 Outstanding Shares17,120,000Market Cap$34.75 million Next Earnings Date2/12/2020 (Estimated) OptionableNot Optionable Receive CODX News and Ratings via Email Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CODX Rates by TradingView Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions What is Co-Diagnostics' stock symbol? Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX." How were Co-Diagnostics' earnings last quarter? Co-Diagnostics Inc (NASDAQ:CODX) announced its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.02. The business earned $0.04 million during the quarter, compared to the consensus estimate of $0.10 million. Co-Diagnostics had a negative return on equity of 202.74% and a negative net margin of 5,486.08%. View Co-Diagnostics' Earnings History. When is Co-Diagnostics' next earnings date? Co-Diagnostics is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Co-Diagnostics. What price target have analysts set for CODX? 2 Wall Street analysts have issued 12-month price objectives for Co-Diagnostics' stock. Their forecasts range from $2.00 to $2.00. On average, they expect Co-Diagnostics' stock price to reach $2.00 in the next twelve months. This suggests that the stock has a possible downside of 1.5%. View Analyst Price Targets for Co-Diagnostics. What is the consensus analysts' recommendation for Co-Diagnostics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Co-Diagnostics. Has Co-Diagnostics been receiving favorable news coverage? News articles about CODX stock have trended very positive on Friday, InfoTrie reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Co-Diagnostics earned a news sentiment score of 3.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Co-Diagnostics. Are investors shorting Co-Diagnostics? Co-Diagnostics saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 600,200 shares, an increase of 9.3% from the November 28th total of 549,200 shares. Based on an average daily trading volume, of 74,500 shares, the short-interest ratio is presently 8.1 days. Approximately 5.6% of the shares of the stock are short sold. View Co-Diagnostics' Current Options Chain. Who are some of Co-Diagnostics' key competitors? Some companies that are related to Co-Diagnostics include Nephros (NEPH), AIT Therapeutics (AITB), Nephros (NEPHD), Sensus Healthcare (SRTS), Pro-Dex (PDEX), STRATA Skin Sciences (SSKN), Motus GI (MOTS), Apollo Endosurgery (APEN), PAVmed (PAVM), T2 Biosystems (TTOO), SANUWAVE Health (SNWV), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), Endologix (ELGX) and Neovasc (NVCN). What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Onconova Therapeutics (ONTX), Sierra Oncology (SRRA), Actinium Pharmaceuticals (ATNM), Inpixon (INPX), Bausch Health Companies (BHC), Advanced Micro Devices (AMD), FuelCell Energy (FCEL), Selecta Biosciences (SELB), Alibaba Group (BABA) and Nokia Oyj (NOK). Who are Co-Diagnostics' key executives? Co-Diagnostics' management team includes the folowing people: Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 66)Dr. Brent C. Satterfield, Co-Founder, Chief Science Officer & Director (Age 42)Mr. Reed L. Benson, CFO, Gen. Counsel & Sec. (Age 71)Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic AlliancesMr. Cameron Gundry, Head of Commercialization LATAM/EUR When did Co-Diagnostics IPO? (CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO. How do I buy shares of Co-Diagnostics? Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Co-Diagnostics' stock price today? One share of CODX stock can currently be purchased for approximately $2.03. How big of a company is Co-Diagnostics? Co-Diagnostics has a market capitalization of $34.75 million and generates $40,000.00 in revenue each year. Co-Diagnostics employs 22 workers across the globe.View Additional Information About Co-Diagnostics. What is Co-Diagnostics' official website? The official website for Co-Diagnostics is http://www.codiagnostics.com/. How can I contact Co-Diagnostics? Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE - D, SALT LAKE CITY UT, 84109. The company can be reached via phone at 801-438-1036 or via email at [email protected] MarketBeat Community Rating for Co-Diagnostics (NASDAQ CODX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 210 (Vote Outperform)Underperform Votes: 239 (Vote Underperform)Total Votes: 449MarketBeat's community ratings are surveys of what our community members think about Co-Diagnostics and other stocks. Vote "Outperform" if you believe CODX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CODX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/24/2020 by MarketBeat.com StaffFeatured Article: What is a stock buyback?
